
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc has demonstrated robust financial performance, with Cell Processing revenue reaching $25.3 million, reflecting a 33% year-over-year growth, while total revenue for 3Q25 was reported at $28.1 million, indicating a 31% year-over-year increase. The company's net income for the quarter stood at $0.6 million, or $0.01 per share, surpassing previous loss estimates and marking a positive shift in financial health. Additionally, management anticipates a gross margin in the low-60% range for 2025, further strengthening the outlook by highlighting operational efficiency and a commitment to reducing net losses.
Bears say
The financial outlook for BioLife Solutions Inc remains cautious due to several inherent risks, including the potential for lower-than-projected growth in its product and service lines, difficulty in securing new customers, and fluctuations in emerging markets and foreign exchange rates. Additionally, the company's revenue guidance for FY2025 reflects a reduction of approximately $8 million related to its evo revenue, indicating challenges in achieving its anticipated growth targets, with projections now suggesting only 27-29% year-over-year growth. Furthermore, the potential for dilution risk adds another layer of uncertainty regarding the company’s financial stability and future performance.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares